Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
Fransson, Åsa; Glaessgen, Daria; Alfredsson, Jessica; Wiman, Klas G; Bajalica-Lagercrantz, Svetlana; Mohell, Nina.
J Ovarian Res
; 9(1): 27, 2016 May 14.
Artigo em Inglês | MEDLINE | ID: mdl-27179933
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient.
Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
A Genomically Characterized Collection of High-Grade Serous Ovarian Cancer Xenografts for Preclinical Testing.
Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas.
APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma.
The molecular pathology of ovarian serous borderline tumors.
Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.
High-grade serous ovarian cancer: the clone wars.